{'fraction_non_alphanumeric': 0.052517203911626224, 'fraction_numerical': 0.03766751177109743, 'mean_word_length': 4.311538461538461, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparison of the pharmacokinetics and thermal antinociceptive pharmacodynamics of 20 μg kg-1 buprenorphine administered sublingually or intravenously in cats.

Little is known about the analgesic action of buprenorphine (BUP) in cats. Relative to man, the cat has a more alkaline oral pH, which may make this an effective route for administering BUP in this species. This study aimed to assess and compare the pharmacokinetics and pharmacodynamics of sublingual (S-L) and IV administration of BUP. 
 
 
 
Thermal threshold (TT) was measured and blood samples were collected following IV or S-L administration (20 µg kg−1) of the injectable formulation. Six cats (five spayed females, one castrated male, 4.1–6.6 kg) were used. Each cat received both treatments in a randomized cross-over study design with 1 month between experiments. Twenty-four hours prior to each study, the lateral thorax of each of the cats was shaved, cephalic and jugular catheters placed, and oral pH measured. On the day of the study, TT was measured using a ‘thorax-mounted’ thermal threshold-testing device specifically developed for cats. The cats were free to move around. Skin temperature was recorded before each test, then the heater activated. When the cat responded by flinching, turning, or jumping, the stimulus was terminated and the threshold temperature was recorded. The thermal threshold cut-off point was 55.5 °C. Three baseline thresholds were recorded before treatment with S-L or IV (via cephalic catheter) BUP (20 µg kg−1). Blood was withdrawn (jugular) at 1, 2, 4, 6, 10, 15, 30, 45, 60 minutes and at 2, 4, 6, 8, 12, and 24 hours post-administration. TT was measured every 30 minutes−6 hours, 1–12 hours, and at 24 hours post-administration. Plasma was immediately separated, stored at −20.5 °C, and assayed within 4 months using a commercially available 125I radioimmunoassay. Threshold data were analyzed using anova with a repeat factor of time. 
 
 
 
No adverse effects were noted. Pupils were dilated for up to 9 hours post-BUP. Behavioral changes were calm euphoria. Measured oral pH was 9 in each cat. Pre-treatment mean threshold (±SD) was 41.2 ± 0.9 °C in the S-L group and 40.8 ± 0.85 °C in the IV group. There were no significant differences between the groups with respect to thresholds over time (p = 0.72). Thresholds were significantly increased from 30 to 360 minutes in both the groups (>44.615 °C). Peak plasma BUP (Cmax) was lower (11 ± 6.7 ng mL−1vs. 92.9 ± 107.9 ng mL−1) and occurred later (Tmax) (30 minutes vs. 1 minute) after S-L compared to IV administration, respectively. 
 
 
 
BUP (20 µg kg−1)-administered S-L or IV provided antinociception between 30 and 360 minutes after administration. Plasma levels did not correspond to TT.